
Charlotte Hedskog

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7426254/publications.pdf Version: 2024-02-01



CHARLOTTE HEDSKOC

#	Article	IF	CITATIONS
1	Realâ€world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan. Journal of Viral Hepatitis, 2021, 28, 129-141.	1.0	5
2	Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. International Journal of Infectious Diseases, 2021, 113, 36-42.	1.5	5
3	Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage. Virus Evolution, 2019, 5, vez041.	2.2	5
4	HIV coâ€infection is associated with increased transmission risk in patients with chronic hepatitis C virus. Journal of Viral Hepatitis, 2019, 26, 1351-1354.	1.0	3
5	Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification. Open Forum Infectious Diseases, 2019, 6, ofz076.	0.4	72
6	Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir. Antiviral Therapy, 2018, 23, 229-238.	0.6	57
7	Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. Journal of Hepatology, 2018, 68, 895-903.	1.8	82
8	Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. Journal of Infectious Diseases, 2018, 218, 1722-1729.	1.9	202
9	HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research, 2018, 158, 178-184.	1.9	17
10	Antiviral response and resistance analysis of treatment-naÃ⁻ve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Research, 2017, 140, 151-157.	1.9	5
11	Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. Journal of Hepatology, 2017, 67, 224-236.	1.8	110
12	L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. Journal of Infectious Diseases, 2016, 213, 1240-1247.	1.9	86
13	Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus. Journal of Clinical Microbiology, 2015, 53, 2049-2059.	1.8	25
14	Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology, 2015, 61, 471-480.	3.6	80